Filing Flows › Ideaya Biosciences (IDYA) › Q2 2026
Ideaya Biosciences (IDYA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Ideaya Biosciences (IDYA) reported revenue of $8.9M for the second quarter 2026 (Q2 2026) and +35% from the quarter before.
Ideaya Biosciences, Q2 2026: revenue $8.9M, net loss $112M, operating cash flow −$88.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.9M | +35% | — |
| Operating profit | −$122M | — | — |
| Net earnings | −$112M | — | — |
| Operating cash flow | −$88.2M | — | — |
What changed
Revenue was $8.9M in Q2 2026, up 35% from the previous quarter.
Operating costs exceeded revenue by $122.3M, an operating margin of -1380.7%. The quarter ended with a net loss of $112.5M, wider than the previous quarter's $98.5M loss.
Operating cash flow was −$88.2M. Non-cash charges added back $688K of depreciation and amortization and $16.7M of share-based compensation. Working capital and other items added $6.9M. Capital expenditures of $866K exceeded it, leaving free cash flow of −$89.1M.
Questions
What was Ideaya Biosciences' revenue in the second quarter 2026?
Ideaya Biosciences (IDYA) reported revenue of $8.9M for the second quarter 2026 (Q2 2026) and +35% from the quarter before.
Source: Ideaya Biosciences 10-Q on SEC EDGAR.